Paid Advertisement
TRYNGOLZA: Expand what’s possible with triglyceride reduction in severe hypertriglyceridemia (sHTG; TGs ≥500 mg/dL)
Presented by Matthew Budoff, MD
Professor of Medicine
David Geffen School of Medicine at UCLA
Endowed Chair of Preventive Cardiology Harbor
UCLA Medical Center
Sunday, November 8, 2026 · 11:15 AM - 12:00 PM · Heart Theater 2, McCormick Place
Severe hypertriglyceridemia (sHTG; triglycerides ≥500 mg/dL) carries a risk of acute pancreatitis that can persist despite diet and conventional lipid-lowering therapy.1-4 This industry-sponsored Expert Theater will focus on the evolving treatment landscape in sHTG, including acute pancreatitis risk, the role of apolipoprotein C-III (apoC-III), and clinical data for TRYNGOLZA® (olezarsen).5,6
On the agenda:
- The clinical burden of sHTG and the relationship between triglyceride levels and acute pancreatitis risk1,7,8
- Why acute pancreatitis risk can persist despite diet and conventional lipid-lowering therapy2-4
- Clinical efficacy and safety data for TRYNGOLZA, including triglyceride lowering and reduction in acute pancreatitis risk5
- The apoC-III–targeted mechanism of action and once-monthly subcutaneous dosing5,6
- Practical considerations for identifying appropriate patients and integrating TRYNGOLZA into clinical practice
- Live faculty Q&A
Seating is limited and available on a first-come basis. Refreshments provided. Visit TRYNGOLZA at Booth #2802 before or after the session.
This event is not part of the official Scientific Sessions Conference 2026 as planned by the American Heart Association Committee on Scientific Sessions Programming.
INDICATION
TRYNGOLZA (olezarsen) is indicated as an adjunct to diet to reduce triglycerides (TG) and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG ≥500 mg/dL).
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred.
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills, and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur.
Liver Enzyme Abnormalities
TRYNGOLZA can cause increases in liver enzymes and hepatic fat in adults. Increases in liver enzymes were more frequently reported with the 80 mg dose as compared with the 50 mg dose. Consider liver enzyme testing before TRYNGOLZA initiation or an increase in dosage and when clinically indicated thereafter. If persistent elevations in liver enzymes occur, consider dose interruption and/or dose reduction. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue TRYNGOLZA.
ADVERSE REACTIONS
Most common adverse reactions in patients with sHTG (incidence ≥2% higher than placebo) were injection site reactions and liver enzyme increases.
Please see full Prescribing Information for TRYNGOLZA, also available at TRYNGOLZAHCP.com.
References
1. Rashid N, Sharma PP, Scott RD, Lin KJ, Toth PP. Severe hypertriglyceridemia and factors associated with acute pancreatitis in an integrated health care system. J Clin Lipidol. 2016;10(4):880-890.
2. Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140(12):e673-e691.
3. Patel SB, Wyne KL, Afreen S, et al. American Association of Clinical Endocrinology clinical practice guideline on pharmacologic management of adults with dyslipidemia. Endocr Pract. 2025;31(2):236-262.
4. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026:S0735-1097(25)10254-4.
5. TRYNGOLZA. Prescribing information. Ionis Pharmaceuticals.
6. Brinton EA, Eckel RH, Gaudet D, et al. Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA. Atherosclerosis. 2025;403:119114.
7. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007;176(8):1113-1120.
8. Kessler AS, Baum SJ, Kutrieb E, et al. Rates of acute pancreatitis and cardiovascular events among adults with severe or extreme hypertriglyceridemia in US clinical practice. Lipids Health Dis. 2025;24(1):252.
©2026 Ionis Pharmaceuticals, Inc. TRYNGOLZA is a registered trademark of Ionis Pharmaceuticals, Inc. All rights reserved.
US-OLZ-2600521 v1.0 09/2026